Incidence and clinical significance of transformation of atrial fibrillation to atrial flutter in patients undergoing long-term antiarrhythmic drug treatment

Europace

Volumn 1, Issue 4, 1999, Pages 242-247

  Riva, S ^a,b   Tondo, C ^a   Carbucicchio, C ^a   Galimberti, P ^a   Fassini, G ^a   Della Bella, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Antiarrhythmic drug treatment; Atrial fibrillation; Atrial flutter

Indexed keywords

ANTIARRHYTHMIC AGENT;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MALE; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 0033206935     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1053/eupc.1999.0048     Document Type: Article

References (35)

1. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation-an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48: 345-71.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
3. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a metaanalysis of randomized control trials. Circulation 1990; 82: 1106-16.
4. Falk RH. Flecainide induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107-11.
5. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141-50.
6. CAST investigators: Preliminary Report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
7. Flaker GC, Blockshear JL, McBride R, Leroumal RA, Holferin JI, Hart RG, on behalf of the Stroke prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20(3): 527-32.
8. Feld GK, Chen P-S, Nicod P, Fleck RP, Meyer D. Possible atrial proarrhythmic effects of Class IC antiarrhythmic drug. Am J Cardiol 1990; 66: 378-83.
9. Murdock CJ, Kyles AE, Yeung-Loi-Wah JA, Qi A, Vorderbrugge S, Kerr CR. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66: 755-7.
10. Brembilla-Perrot B, Terrier de la Chaise A. Provocation of supraventricular tachycardias by an intravenous Class I antiarrhythmic drug. Int J Cardiol 1992; 34: 189-98.
11. Tunick PA, McElhinney L, Mitchell T, Kronzai I. The alternation between atrial flutter and atrial fibrillation. Chest 1992; 101: 34-6.
12. Lévy S, Novella P, Ricard P and Paganelli F. Paroxysmal atrial fibrillation: A need for classification. J Cardiovasc Electrophysiol 1995; 6: 69-74.
13. Waldo AL, MacLean WAH. Diagnosis and treatment of arrhythmias following open heart surgery: emphasis on the use of epicardial wire electrodes. Armonk; NY: Futura Publishing Company, 1980.
14. Watson RM, Josephson ME. Atrial flutter, 1: electrophysiologic substrate and modes of initiation and termination in humans. Circulation 1992; 86: 375-81.
15. Allessie MA, Rensma PL, Brugada J, Smeets JLRM, Penn OC, Kirchhof CJMS. Pathophysiology of atrial fibrillation. In: Zipes DP, Jalife J eds. Cardiac electrophysiology: From cell to bedside. Philadelphia: WB Saunders Company, 1990: 548-58.
16. Waldo AL. Mechanisms of atrial fibrillation, atrial flutter, and ectopic atrial tachycardia: a brief review. Circulation 1987; 75 (Suppl III): III 37-40.
17. Ortiz J, Niwano S, Abe H, Rudy Y, Johnson NJ, Waldo AL. Mapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. Circ Res 1994; 75: 882-94.
18. Pagé PL, Hassanalizadeh H, Cardinal R. Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dog with sterile pericarditis. Can J Physiol Pharmacol 1991; 69: 15-24.
19. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992; 70: 56A-60A.
20. Camm AJ, Ward D, Spurrell R. Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination. Br Heart J 1980; 44: 240-7.
21. Waldo AL, MacLean WAH, Karp RB et al. Entrainment and interruption of atrial flutter with atrial pacing. Circulation 1977; 56: 737-45.
22. Klein H, Werner PC. Atrial pacing in acute treatment of atrial flutter. In Waldo AL, Touboul P, eds. Atrial Flutter: Advances in mechanisms and management. Armonk, NY: Futura Publishing Company, 1996: 375-86.
23. Della Bella P, Tondo C, Carbucicchio C, Riva S. The excitable gap of type I atrial flutter in humans. In: Waldo AL, Touboul P, eds. Atrial flutter: advances in mechanisms and management. Armonk, NY: Futura Publishing Company, 1996: 259-68.
24. Aliot E. Role of drugs to control atrioventricular conduction during atrial flutter. In: Waldo AL, Touboul P, eds. Atrial flutter: advances in mechanisms and management. Armonk, NY: Futura Publishing Company 1996: 363-8.
25. Della Bella P, Carbucicchio C, Tondo C, Riva S. Modulation of the atrioventricular conduction by ablation of the 'slow' pathway in patients with drug refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25: 39-46.
26. Della Bella P, Marenzi G, Tondo C et al. Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing. Am J Cardiol 1989; 63: 812-6.
27. Doni F, Della Bella P, Kheir A et al. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995; 76: 1243-6.
28. Keane D, Sulke N, Cooke R, Jackson G, Sowton E. Endocardial cardioversion of atrial flutter and fibrillation (Abstr). PACE 1993; 16: 928.
29. Murgatroyd FD, Camm AJ. Atrial arrhythmias: Who would be a candidate for an implantable atrial defibrillator? In: Waldo AL, Touboul P, eds. Atrial flutter: advances in mechanisms and management. Armonk, NY: Futura Publishing Company, 1996: 427-38.
30. Kalman JM, Olgin JE, Saxon LA, Lee RJ, Schienman MM, Lesh MD. Electrocardiographic and electrophysiologic characterization of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 1997; 8: 121-44.
31. Cosio FG, Lopez-Gil M, Goicolea A et al. Radiofrequency ablation of the inferior vena cava-tricuspid valve isthmus in common atrial flutter. Am J Cardiol 1993; 71: 705-9.
32. Fisher B, Haissaguerre M, Garrigues S et al. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25: 1365-72.
33. Lesh MD, Van Hare GF, Epstein LM et al Radiofrequency catheter ablation of atrial arrhythmias - Results and mechanisms. Circulation 1994; 89: 1074-89.
34. Philippon F, Plumb VJ, Epstein AE, Kay GN. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. Circulation 1995; 92: 430-5.
35. Saxon La, Kalman JM, Olgin JE, Sheinmann MM, Lee RJ, Lesh MD. Results of radiofrequency catheter ablation for atrial flutter. Am J Cardiol 1996; 77: 1014-6.